Advicenne (ALDVI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Advicenne (ALDVI) has a cash flow conversion efficiency ratio of -0.099x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.89 Million ≈ $2.20 Million USD) by net assets (€-19.07 Million ≈ $-22.30 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Advicenne - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Advicenne's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Advicenne (ALDVI) financial obligations for a breakdown of total debt and financial obligations.
Advicenne Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Advicenne ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ryukil C&S Ltd
KQ:191410
|
-0.033x |
|
Tek Seng Holdings Bhd
KLSE:7200
|
0.087x |
|
INIFY LABORATORIES AB
F:WY60
|
N/A |
|
Hammer Metals Ltd
AU:HMX
|
-0.019x |
|
IMS SA
WAR:IMS
|
0.157x |
|
Rohas Tecnic Bhd
KLSE:9741
|
-0.031x |
|
PN Poong Nyun Co. Ltd
KQ:024940
|
0.037x |
|
Milestone Scientific
NYSE MKT:MLSS
|
0.032x |
Annual Cash Flow Conversion Efficiency for Advicenne (2015–2024)
The table below shows the annual cash flow conversion efficiency of Advicenne from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Advicenne stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-19.07 Million ≈ $-22.30 Million |
€-762.00K ≈ $-890.86K |
0.040x | -92.01% |
| 2023-12-31 | €-11.97 Million ≈ $-13.99 Million |
€-5.99 Million ≈ $-7.00 Million |
0.500x | -41.93% |
| 2022-12-31 | €-10.62 Million ≈ $-12.41 Million |
€-9.15 Million ≈ $-10.69 Million |
0.862x | +102.13% |
| 2021-12-31 | €309.00K ≈ $361.25K |
€-12.53 Million ≈ $-14.64 Million |
-40.534x | -1034.15% |
| 2020-12-31 | €3.27 Million ≈ $3.83 Million |
€-11.69 Million ≈ $-13.67 Million |
-3.574x | -538.39% |
| 2019-12-31 | €16.92 Million ≈ $19.79 Million |
€-9.47 Million ≈ $-11.08 Million |
-0.560x | -62.93% |
| 2018-12-31 | €29.63 Million ≈ $34.64 Million |
€-10.18 Million ≈ $-11.90 Million |
-0.344x | -98.49% |
| 2017-12-31 | €33.51 Million ≈ $39.18 Million |
€-5.80 Million ≈ $-6.78 Million |
-0.173x | -1230.87% |
| 2016-12-31 | €-5.15 Million ≈ $-6.02 Million |
€67.00K ≈ $78.33K |
-0.013x | -100.81% |
| 2015-12-31 | €-1.67 Million ≈ $-1.95 Million |
€-2.69 Million ≈ $-3.15 Million |
1.613x | -- |
About Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or co… Read more